Drug-target interaction prediction: Databases, web servers and computational models

Briefings in Bioinformatics

Volumn 17, Issue 4, 2016, Pages 696-712

  Chen, Xing ^a   Yan, Chenggang Clarence ^b   Zhang, Xiaotian ^c   Zhang, Xu ^c   Dai, Feng ^a   Yin, Jian ^c   Zhang, Yongdong ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b TSINGHUA UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Biological networks; Computational models; Drug discovery; Drug target interactions prediction; Machine learning

Indexed keywords

DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; FACTUAL DATABASE; HUMAN;

DATABASES, FACTUAL; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS;

EID: 84991328213     PISSN: 14675463     EISSN: 14774054     Source Type: Journal    
DOI: 10.1093/bib/bbv066     Document Type: Article

References (89)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-15.
2. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;9:203-14.
3. Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 2004;3:417-29.
4. Chen H, Zhang Z. A semi-supervised method for drug-target interaction prediction with consistency in networks. PLoS One 2013;8:e62975.
5. Booth B, Zemmel R. Prospects for productivity. Nat Rev Drug Discov 2004;3:451-6.
6. Wang Y, Zeng J. Predicting drug-target interactions using restricted Boltzmann machines. Bioinformatics 2013;29:i126-34.
7. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682-90.
8. Iskar M, Zeller G, Zhao X-M, et al. Drug discovery in the age of systems biology: the rise of computational approaches for data integration. Curr Opin Biotechnol 2012;23:609-16.
9. Yamanishi Y, Araki M, Gutteridge A, et al. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 2008;24:i232-40.
10. Chen X, Liu M-X, Yan G-Y. Drug-target interaction prediction by random walk on the heterogeneous network. Mol Biosyst 2012;8:1970-8.
11. MacDonald ML, Lamerdin J, Owens S, et al. Identifying offtarget effects and hidden phenotypes of drugs in human cells. Nat Chem Biol 2006;2:329-37.
12. Xie L, Xie L, Kinnings SL, et al. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Ann Rev Pharmacol Toxicol 2012;52:361-79.
13. Yang K, Bai H, Ouyang Q, et al. Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol 2008;4:228.
14. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007;12:34-42.
15. Frantz S. Drug discovery: playing dirty. Nature 2005;437:942-3.
16. Allen JA, Roth BL. Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Ann Rev Pharmacol Toxicol 2011;51:117-44.
17. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-83.
18. Nú ñ ez S, Venhorst J, Kruse CG. Target-drug interactions: first principles and their application to drug discovery. Drug Discov Today 2012;17:10-22.
19. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006;5:821-34.
20. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993-6.
21. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-30.
22. Drews J. Drug discovery: a historical perspective. Science 2000;287:1960-4.
23. Golden J. Prioritizing the human genome: knowledge management for drug discovery. Curr Opin Drug Discov Dev 2003;6:310-16.
24. Zheng C, Han L, Yap CW, et al. Progress and problems in the exploration of therapeutic targets. Drug Discov Today 2006;11:412-20.
25. Landry Y, Gies JP. Drugs and their molecular targets: an updated overview. Fundam Clin Pharmacol 2008;22:1-18.
26. Wheeler DL, Barrett T, Benson DA, et al. Database resources of the national center for biotechnology information. Nucleic Acids Res 2007;35:D5-12.
27. Sayers EW, Barrett T, Benson DA et al. Database resources of the national center for biotechnology information. Nucleic Acids Res 2011;39:D38-51.
28. Dobson CM. Chemical space and biology. Nature 2004;432:824-8.
29. Yu H, Chen J, Xu X, et al. A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS One 2012;7:e37608.
30. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006;34:D354-7.
31. Stockwell BR. Chemical genetics: ligand-based discovery of gene function. Nat Rev Genet 2000;1:116-25.
32. Chen L, Zeng W-M. A two-step similarity-based method for prediction of drug's target group. Protein Pept Lett 2013;20:364-70.
33. Huang T, Tu K, Shyr Y, et al. The prediction of interferon treatment effects based on time series microarray gene expression profiles. J Transl Med 2008;6:44.
34. Huang T, Cui W, He Z-S, et al. Functional association between influenza A (H1N1) virus and human. Biochem Biophys Res Commun 2009;390:1111-13.
35. Giuliano KA, Haskins JR, Taylor DL. Advances in high content screening for drug discovery. Assay Drug Dev Technol 2003;1:565-77.
36. Hughes JE. Genomic technologies in drug discovery and development. Drug Discov Today 1999;4:6.
37. Petriz BA, Gomes CP, Rocha LA, et al. Proteomics applied to exercise physiology: a cutting-edge technology. J Cell Physiol 2012;227:885-98.
38. Ma H, Zhao H. Drug target inference through pathway analysis of genomics data. Adv Drug Deliv Rev 2013;65:966-72.
39. Haggarty SJ, Koeller KM, Wong JC, et al. Multidimensional chemical genetic analysis of diversity-oriented synthesisderived deacetylase inhibitors using cell-based assays. Chem Biol 2003;10:383-96.
40. Kuruvilla FG, Shamji AF, Sternson SM et al. Dissecting glucose signalling with diversity-oriented synthesis and smallmolecule microarrays. Nature 2002;416:653-7.
41. Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 2014;42:D1091-7.
42. Qin C, Zhang C, Zhu F, et al. Therapeutic target database update 2014: a resource for targeted therapeutics. Nucleic Acids Res 2014;42:D1118-23.
43. Hecker N, Ahmed J, von Eichborn J, et al. SuperTarget goes quantitative: update on drug-target interactions. Nucleic Acids Res 2012;40:D1113-17.
44. Günther S, Kuhn M, Dunkel M, et al. SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res 2008;36:D919-22.
45. Kuhn M, Szklarczyk D, Pletscher-Frankild S, et al. STITCH 4: integration of protein-chemical interactions with user data. Nucleic Acids Res 2014;42:D401-7.
46. Magariñ os MP, Carmona SJ, Crowther GJ, et al. TDR Targets: a chemogenomics resource for neglected diseases. Nucleic Acids Res 2012;40:D1118-27.
47. Gao Z, Li H, Zhang H, et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008;9:104.
48. Gaulton A, Bellis LJ, Bento AP, et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 2012;40:D1100-7.
49. Emig D, Ivliev A, Pustovalova O, et al. Drug target prediction and repositioning using an integrated network-based approach. PLoS One 2013;8:e60618.
50. Kuhn M, Campillos M, Letunic I, et al. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 2010;6:343.
51. Seiler KP, George GA, Happ MP, et al. ChemBank: a smallmolecule screening and cheminformatics resource database. Nucleic Acids Res 2008;36:D351-9.
52. Pawson AJ, Sharman JL, Benson HE, et al. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res 2014;42:D1098-106.
53. Kumar R, Chaudhary K, Gupta S, et al. CancerDR: cancer drug resistance database. Sci Rep 2013;3:1445.
54. Liu T, Lin Y, Wen X, et al. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 2007;35:D198-201.
55. Irwin JJ, Sterling T, Mysinger MM, et al. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 2012;52:1757-68.
56. Halling-Brown MD, Bulusu KC, Patel M, et al. canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res 2012;40:D947-56.
57. Roth BL. Psychoactive Drug Screening Program, Contract No. HHSN-271-2008-00025-C (NIMH PDSP) 2008. http://pdsp.med. unc.edu/.
58. Liu Y, Hu B, Fu C, et al. DCDB: drug combination database. Bioinformatics 2010;26:587-8.
59. Giordano S, Petrelli A. From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008;15:422-32.
60. Chen X, Ren B, Chen M, et al. ASDCD: antifungal synergistic drug combination database. PLoS One 2014;9:e86499.
61. Yamanishi Y, Kotera M, Moriya Y, et al. DINIES: drug-target interaction network inference engine based on supervised analysis. Nucleic Acids Res 2014;42:W39-45.
62. Nickel J, Gohlke B-O, Erehman J, et al. SuperPred: update on drug classification and target prediction. Nucleic Acids Res 2014;42:W26-31.
63. Gfeller D, Grosdidier A, Wirth M, et al. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res 2014;42:W32-8.
64. Whitebread S, Hamon J, Bojanic D, et al. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today 2005;10:1421-33.
65. Cheng AC, Coleman RG, Smyth KT, et al. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 2007;25:71-5.
66. Donald BR. Algorithms in Structural Molecular Biology. Cambridge, MA: MIT Press, 2011.
67. Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785-91.
68. Campillos M, Kuhn M, Gavin A-C, et al. Drug target identification using side-effect similarity. Science 2008;321:263-6.
69. Cheng F, Liu C, Jiang J, et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol 2012;8:e1002503.
70. Hattori M, Okuno Y, Goto S, et al. Development of a chemical structure comparison method for integrated analysis of chemical and genomic information in the metabolic pathways. J Am Chem Soc 2003;125:11853-65.
71. Smith TF, Waterman MS. Identification of common molecular subsequences. J Mol Biol 1981;147:195-7.
72. Shi J-Y, Liu Z, Yu H, et al. Predicting drug-target interactions via within-score and between-score. BioMed Res Int 2015;2015:350983.
73. Bleakley K, Yamanishi Y. Supervised prediction of drug-target interactions using bipartite local models. Bioinformatics 2009;25:2397-403.
74. Yamanishi Y, Kotera M, Kanehisa M, et al. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 2010;26:i246-54.
75. Mei J-P, Kwoh C-K, Yang P, et al. Drug-target interaction prediction by learning from local information and neighbors. Bioinformatics 2013;29:238-45.
76. Cao DS, Zhang LX, Tan GS, et al. Computational prediction of drugtarget interactions using chemical, biological, and network features. Mol Inform 2014;33:669-81.
77. Wang JT, Liu W, Tang H, et al. Screening drug target proteins based on sequence information. J Biomed Inform 2014;49:269-74.
78. Xia Z, Wu L-Y, Zhou X, et al. Semi-supervised drug-protein interaction prediction from heterogeneous biological spaces. BMC Syst Biol 2010;4:S6.
79. Pahikkala T, Airola A, Pietilä S, et al. Toward more realistic drug-target interaction predictions. Brief Bioinform 2015;16:325-37.
80. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature 2009;462:175-81.
81. Cobanoglu MC, Liu C, Hu F, et al. Predicting drug-target interactions using probabilistic matrix factorization. J Chem Inform Model 2013;53:3399-409.
82. Wang E, Zou J, Zaman N, et al. Cancer systems biology in the genome sequencing era: part 2, evolutionary dynamics of tumor clonal networks and drug resistance. Semin Cancer Biol 2013;23:286-92.
83. Wang E, Zaman N, Mcgee S, et al. Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. Semin Cancer Biol 2015;30:4-12.
84. Wang E, Zou J, Zaman N, et al. Cancer systems biology in the genome sequencing era: part 1, dissecting and modeling of tumor clones and their networks. Semin Cancer Biol 2013;23:279-85.
85. Metz JT, Johnson EF, Soni NB, et al. Navigating the kinome. Nat Chem Biol 2011;7:200-2.
86. Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011;29:1046-51.
87. Park Y, Marcotte EM. Flaws in evaluation schemes for pair-input computational predictions. Nat Methods 2012;9:1134-36.
88. Chen X, Yan G-Y. Novel human lncRNA-disease association inference based on lncRNA expression profiles. Bioinformatics 2013;29:2617-24.
89. Ding H, Takigawa I, Mamitsuka H, et al. Similarity-based machine learning methods for predicting drug-target interactions: a brief review. Brief Bioinform 2014;15:734-47.